Jimmy Pruitt, PharmD
@pharmdintheed.bsky.social
310 followers
310 following
27 posts
EM PharmD. PGY1 AdventHealth Orlando➡️PGY2 EM Grady. Views are my own. Founder Pharm So Hard Network + PharmacyAcute.com + @emprx25.bsky.social
Posts
Media
Videos
Starter Packs
Big news! Meet the powerhouse editors of the new Journal of Acute Care Pharmacotherapy (#JACP):
• EIC: Dr. Brian Gilbert
• Deputy EIC: Dr. Christopher Edwards
Leaders from the frontlines of acute care.
#SEMP #PharmacyLeadership #JACP #ForUsByUs #AcuteCare
• EIC: Dr. Brian Gilbert
• Deputy EIC: Dr. Christopher Edwards
Leaders from the frontlines of acute care.
#SEMP #PharmacyLeadership #JACP #ForUsByUs #AcuteCare
Reposted by Jimmy Pruitt, PharmD
Reposted by Jimmy Pruitt, PharmD
Reposted by Jimmy Pruitt, PharmD
Reposted by Jimmy Pruitt, PharmD
Day 2 of #EMPowerRx2025 is HERE and we're bringing the HEAT!
4 Days of EM Pharmacotherapy in a cost conscious manner. You can join us in person or virtual for all of it!
See you there! empowerx-conference.com
👋 #pharmacy #emergencymedicine #EMRx #EMRx
4 Days of EM Pharmacotherapy in a cost conscious manner. You can join us in person or virtual for all of it!
See you there! empowerx-conference.com
👋 #pharmacy #emergencymedicine #EMRx #EMRx
📢 HUGE ANNOUNCEMENT! We've added a VIRTUAL Day 1 to #EMPowerX25! 🎉 Double the content, double the learning! Join us online for critical EM topics on 4/3/2025. Check out the more about the conference: empowerx-conference.com
#EMRx #EMPRx25 #MedEd
#EMRx #EMPRx25 #MedEd
Reposted by Jimmy Pruitt, PharmD
Reposted by Jimmy Pruitt, PharmD
Reposted by Jimmy Pruitt, PharmD
Reposted by Jimmy Pruitt, PharmD
An investigation published by The BMJ raised concerns over the 15 years' old landmark PLATO that was used to gain worldwide approval for AstraZeneca's anti-platelet drug ticagrelor (Brilinta in 🇺🇸)
🔥 FDA just *rejected* full approval for Adnexxa 🔥
likely due to increased thrombosis risk in ANEXA-I trial
IMHO the best strategy is to keep this off your hospital's formulary (thereby avoiding endless circular debates about Adnexxa vs PCC)
firstwordpharma.com/story/5921956 #EMIMCC
likely due to increased thrombosis risk in ANEXA-I trial
IMHO the best strategy is to keep this off your hospital's formulary (thereby avoiding endless circular debates about Adnexxa vs PCC)
firstwordpharma.com/story/5921956 #EMIMCC
FirstWord
firstwordpharma.com
Reposted by Jimmy Pruitt, PharmD
Daily insulin injections can be a burden for patients with type 2 diabetes. Insulin efsitora is a new basal insulin that can be given once weekly. Research findings comparing efsitora with degludec are summarized in a new Quick Take video. youtu.be/miNU6siDB1E
#EndoSky #MedSky
#EndoSky #MedSky
Insulin Efsitora versus Degludec in Type 2 Diabetes | NEJM
YouTube video by NEJM Group
youtu.be